ArticleBlood2011
"Let"-ing go with clonal expansion?
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- The High Mobility Group A1 (HMGA1) gene is highly overexpressed in human uterine serous carcinomas and carcinosarcomas and drives Matrix Metalloproteinase-2 (MMP-2) in a subset of tumors.Gynecologic oncology · 2016Article
- The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.Current molecular medicine · 2016Review
- The high mobility group A1 molecular switch: turning on cancer - can we turn it off?Expert opinion on therapeutic targets · 2014Review
- Hitting the bull's eye: targeting HMGA1 in cancer stem cells.Expert review of anticancer therapy · 2014Article
- HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks.PloS one · 2012Article
- HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells.PloS one · 2012Article
- HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis.BMC genomics · 2011Article
- The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In this issue of Blood, Ikeda et al report the effects of the high mobility group A2 (Δhmga2) lacking the 3' untranslated region (UTR) in hematopoietic tissues. Overexpression of Δhmga2 in transgenic mice resulted in "big mice with big blood": the mice weighed more and had a myeloproliferative phenotype with increases in peripheral blood counts, splenomegaly, a hypercellular bone marrow and erythropoietin-independent erythroid colony formation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.